BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Rivus Scores $132M to Advance Obesity Drug, Cardio-Metabolic Pipeline

  Rivus raised $132 million in a Series B financing round that will be used in developing HU6, a new drug class designed to treat cardio-metabolic disease by addressing obesity.

  September 22, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  GSK Swoops in to Save Spero, Late-Stage Antibiotic

  Shares of Spero Therapeutics soared in premarket trading following GlaxoSmithKline’s announcement that it will license the company’s late-stage antibiotic asset, tebipenem HBr.

  September 22, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  The Search for the Fountain of Longevity, not Youth

  Several biotech companies backed by billions are working on different approaches to developing the next big anti-aging therapy - from blood experiments to cell reprogramming.

  September 22, 2022

   · 

  8 min read

   · 

  Ignacio Guerrero-Ros, Ph.D.
• 

  Drug Development

  Calibr, Synthego, BlueSphere and More Showcase Data at CAR-TCR Summit

  The 7th Annual CAR-TCR Summit is ongoing in Boston, with more than 1,000 experts in CAR and TCR technologies attending. Here’s a look at some of the latest research and data being presented.

  September 22, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Novartis Unveils Path to Becoming a Top 5 US Player by 2027

  Novartis outlined how its transformation to a pure-play innovative medicines company is nearly completed during a “Meet the Management” event in Switzerland.

  September 22, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Novo’s Once-Weekly Insulin Treatment Part of a Transforming T2D Space

  New data from Novo Nordisk’s Phase IIIa ONWARD 2 trial studying insulin icodec shows it is effective as a once-weekly treatment for Type 2 diabetes.

  September 22, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Allogene Stocks Fall as Servier Abandons Anti-CD19 Partnership

  Allogene Therapeutics’ French partner Servier has withdrawn all involvement in the development of Allogene’s anti-CD19 products, allowing Allogene to license its CD19 products outside the U.S.

  September 22, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More

  Alaunos Therapeutics, Satsuma Pharmaceuticals, NeuroSense, Emyria and more reported updates in solid tumors, migraine, ALS and MDMA drug discovery.

  September 22, 2022

   · 

  4 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Movers & Shakers: New CEOs at 7 Biopharma Companies

  Seven biopharma companies are under new leadership. This week’s Movers & Shakers highlights these new chief executive officers who aim to guide their companies into the future.

  September 22, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  Cancer Vaccines Push Toward Viability with New Approaches and Targets

  Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.

  September 22, 2022

   · 

  6 min read

   · 

  Gail Dutton